期刊文献+

柔红霉素联合阿糖胞苷治疗急性髓系白血病有效性及安全性分析 被引量:2

原文传递
导出
摘要 目的分析柔红霉素联合阿糖胞苷治疗急性髓系白血病的有效性及安全性。方法选取2017年7月~2018年9月我院急性髓系白血病患者作为研究对象,共82例,依据随机数字表法分为对照组、观察组,各41例。两组均给予常规干预,对照组采用阿糖胞苷治疗,观察组采用柔红霉素+阿糖胞苷治疗。比较两组临床疗效、不良反应发生率。结果两组治疗总有效率比较,观察组90.24%高于对照组70.73%,差异具有统计学意义(P<0.05);治疗后,观察组不良反应发生率(46.34%)与对照组(75.61%)相比显著降低,差异具有统计学意义(P<0.05)。结论柔红霉素联合阿糖胞苷治疗急性髓系白血病疗效显著,不良反应少,值得推广应用。
作者 董存山
出处 《首都食品与医药》 2020年第8期59-59,共1页 Capital Food Medicine
  • 相关文献

参考文献2

二级参考文献30

  • 1Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010.CA Cancer J Clin,2010,60:277-300.
  • 2Meshinchi S,Arceci RJ.Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.Oncologist,2007,12;341-355.
  • 3O'Brien MM,Cao X,Pounds S,et al.Prognostic features in acute megakaryoblastie leukemia in children without Down syndrome;a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421.Leukemia,2013,27:731-734.
  • 4Quintas-Cardama A,Santos FP,Garcia-Manero G.Histone deacetylase inhibitors for die treatment of myelodysplastic syndrome and acute myeloid leukemia.Leukemia,2011,25;226-235.
  • 5Bolden JE,Peart MJ,Johnstone RW.Anticancer activities of histone deacetylase inhibitors.Nat Rev Drug Discov,2006,5;769-784.
  • 6Marks PA.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Expert Opin Investig Drugs,2010,19;1049-1066.
  • 7Garcia-Manero G,Assouline S,Cortes J,et al.Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.Blood,2008,112:981-989.
  • 8Garcia-Manero G,Yang H,Bueso-Ramos C,et al.Phase 1 study of the histone deacetylase inhibitor vorinostat(suberoylanilide hydroxamic acid[SAHA])in patients with advanced leukemias and myelodysplastic syndromes.Blood,2008,111;1060-1066.
  • 9Maiso P,Colado E,Ocio EM,et al.The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.Leukemia,2009,23:2265-2274.
  • 10Shiozawa K,Nakanishi T,Tan M,et al.Preclinical studies of vorinostat(suberoylanilide hydroxamic acid)combined with cytosine arabinoside and etoposide for treatment of acute leukemias.Clin Cancer Res,2009,15:1698-1707.

共引文献4

同被引文献17

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部